Design and Development of Cell-Based Potency Assays for Biologics Targeting T-Cell Co-Stimulation and Co-inhibition Pathways

Size: px
Start display at page:

Download "Design and Development of Cell-Based Potency Assays for Biologics Targeting T-Cell Co-Stimulation and Co-inhibition Pathways"

Transcription

1 Design and Development of Cell-Based Potency Assays for Biologics Targeting T-Cell Co-Stimulation and Co-inhibition Pathways Shihua Lin, PhD. Senior Scientist Analytical Biotechnology Development, MedImmune One MedImmune Way, Gaithersburg, MD April 4-5, 2016 Silver Spring, MD

2 Outline of today s talk Introduction: T cell & Cancer immunotherapy Understanding T cell co-signaling molecules and pathways Cell-based potency assay for therapeutic biologics Design and Development of improved cell-based assays for biologics targeting: T cell co-stimulation pathways T cell co-inhibition pathways 2

3 Introduction T Cell Anti-Cancer Responses 4 T cells can recognize tumor antigens but its anti-cancer responses are suppressed via 1) T cell-intrinsic mechanisms such as expression of checkpoint proteins (PD-1, CTLA-4) lead to T cell exhaustion, 2) tumor-intrinsic mechanisms such as secretion of suppressive factors, and 3) suppressive cells such as Treg cells and tumor-associated macrophages. Adopted from Rambam Maimonides Med J Jan; 6(1): e0004

4 T cell and Cancer immunotherapy T cells play a central role in cell-mediated immunity in the body Therapy that targets T cell signaling pathways is now a major field of immunotherapy for a number of diseases The successful use of CTLA4 fusion proteins (abatacept, belatacept) for the treatment of RA represents an important milestone in this field Approval of CTLA4-Ab (ipilimumab) provides clear evidence for the efficacy of immunotherapy targeting T cell co-signaling Positive clinical results of PD1 (Keytruda ) and B7-H1 Abs provide significant impact on the trends of cancer drug development 4 New therapy strategies are being developed to target one or more T cell co-signaling molecules/pathways.

5 T cell function and co-signaling T cell function regulation Two-signal model (MHC/TCR, Co-signaling) Definition of T cell co-signaling -- Cell surface molecules that transduce signals into T cells to modulate TCR and other signaling T cell co-signaling receptors often colocalize with TCR at the immunological synapse T cell co-signaling regulation is determined by the type of ligands and counter receptors Co-signaling ligands and counter-receptors have now been identified on nearly all cell types 6

6 T cell co-signaling pathways T cell co-signaling Co-stimulation Co-inhibition Main co-signaling receptors for T cells: Immunoglobulin (Ig) superfamily: - CD28 and B7 families TNF receptor superfamily: - CD27, CD134, GITR 6 Co-signaling molecules have a crucial role: Regulation of T cell activation Subset differentiation Survival and proliferation Effector functions

7 Downstream pathways of T cell co-signaling Downstream of co-stimulation Downstream of co-inhibition T cell co-stimulation and co-inhibition share some downstream pathways 7 8 Nat Rev Immunol. 13(4): (2013)

8 Understanding of T cell co-signaling is evolving Co-stimulation receptors Co-inhibition receptors 9 Nat Rev Immunol. 13(4): (2013) 8

9 Cell-based potency assay for therapeutic biologics Conventional potency assays: Assessing Fab and Fc function using 2 or more assays Release assay Use a target-expressing cell line to evaluate drug potency --- focus on Fab portion only Characterization assay Use a binding assay and/or cellbased assay to evaluate Fc effector function --- focus on Fc portion only T Y Adapted from wikipedia 10 Conventional potency assays: Evaluate Fab and Fc function separately Do not mimic in vivo condition

10 Considering in vivo environment Expression of FcR is found on most blood cells FcRs CD Distribution FcγRI CD64 Monocyte, macrophage, DC, neutrophil, eosinophil FcγRII CD32 Monocyte, macrophage, DC, platelet, neutrophil, NK FcγRIII CD16 Monocyte, macrophage, DC, neutrophil, eosinophil, mast cell, NK D P M NK N T Y Eo B Mac Adapted from wikipedia 11 Adapted from wikipedia Target cells are surrounded by various blood cells. Therapeutic biologics interact with target cells (via Fab) and FcRs expressing cells (via Fc).

11 Assay design for T cell co-stimulating biologics (1) 1. One-cell method 2. One-cell plus stimulator AbX Target Receptor Y TCR p/gene Luc YYYY Y Y AbX TCRL Target Receptor TCR p/gene Luc Engineered target cell with reporter gene Target cell plus plate-bound cross-linking 3. Two-cell method Effecter cell Target cell FcRs Y AbX Target Receptor p/gene Luc TCR 12 FcR expressing effector cell and engineered target cell

12 Assay design for T cell co-stimulating biologics (2) 4. Two-cell plus (2-Cell + ) assay: 2-Cell + Assay = Effector cell + Target cell + Co-stimulator Effector Target Receptor Target FcRs AbX Y Y TCRL TCR p/gene Luciferase 13 Key features: Engage drug s Fc and Fab function in one assay. Add 2 nd stimulator to enhance co-signaling activation.

13 Development of 2-cell + bioassay for T cell co-stimulating biologics Assay Procedures 1 2 Prepare assay buffer Serially dilute AbX RLU Add AbX dilutions Add target & APCs Incubate at 37 C Add Steady-Glo and read plates TCRL 100x TCRL 10x TCRL 1x TCRL TCRL [AbX] Cell Assay Cell + Assay Cell Assay AbX induced strong T cell activation signals in 2-cell + system. 2-Cell + Assay = Effector cell + Target cell + Co-stimulator 13

14 Assay performance of 2-cell + assay Linearity Stability sample testing RP% of stressed samples Observed RP% RLU [Ab] RLU Specificity testing O RS Control AbX Anti-CD16 Anti-CD64 O Formulation buffer 15 Expected RP% [Ab] The assay also has high accuracy and precision. 2-Cell + Assay = Effector cell + Target cell + Co-stimulator

15 Characterization of 2-cell + assay (1) AbX with different Fc formats (IgG1 vs. IgG4) Drugs Fab Fc IgG1 vs. IgG4 AbX (IgG1) Fab + Fc AbX (IgG4) Target cell Effector cell AbX-hIgG1 RLU AbX-hIgG4 [Ab] 16 2-Cell + assay is capable of distinguishing AbX molecules in different IgG formats. 2-Cell + Assay = Effector cell + Target cell + Co-stimulator

16 Characterization of 2-cell + assay (2) TCRL (intact) vs. Enzyme digested TCRL Enzyme TCRL (Ab) Fab + Fc Effector Target Receptor Target FcRs AbX Y YTCRL? TCR p/gene Luciferase RLU 2-Cell Assay 2-Cell + Assay (w/ TCRL) 2-Cell + Assay (w/ Enzyme digested TCRL) 17 [Ab] Binding of TCRL to TCR plays an important role on T cell activation. 2-Cell + Assay = Effector cell + Target cell + Co-stimulator

17 2-cell + vs. Other formats for T cell co-stimulating biologics 1-Cell Assay 1-Cell + Costimulator 2-Cell Assay 2-Cell + Assay Assay Design Target cell only Target cell Co-stimulator Target cell Effecter cell Target cell Effecter cell Co-stimulator Engage Fab & Fc? No No (no FcR involved) Yes Yes Signal? Easy to perform? MOA Reflective? Yes for target molecule No for T cell costimulation Yes for target molecule Yes for T cell costimulation Yes for target molecule No for T cell costimulation Yes for target molecule Yes for T cell co-stimulation 18 Compared to one-cell assays, the 2-cell + assay is one step closer to mimicking in vivo conditions.

18 Assay design for T cell co-inhibitory biologics MOA of AbY AbY Ligand Assay Procedures 1 Prepare assay buffer 2 Serially dilute AbY APC Assay Design B7 MHC B7 AbY Target TCR CD28 p/gene Luc Target cell Add AbY dilutions Add target & APCs Incubate at 37 C Add Steady-Glo and read plates 19 Stimulator

19 Assay development for T cell co-inhibitory biologics Time course 1 Time course 2 RLU RLU StdCu e Specificity Assay characterization RS Ctrl RLU RS AbY Other Ab1 Other Ab2 RLU No stimulator No AbY No APC No Target Other Ab3 [Ab] [Ab] 20 The assay has been validated with good Accuracy, Linearity, and Precision. The assay is also robust, stability indicative, and product specific.

20 Summary A potency assay should be product-specific and reflect the MOA. Since full activation of T cells often requires the interaction of two or more-signals, co-signaling pathway(s) should be considered during assay design and development. For T cell co-stimulating biologics, conventional one-cell potency assays tend to be oversimplified, the 2-cell + assay shown here is: Capable of monitoring Fab and Fc in one assay MOA-reflective for target molecule MOA-reflective for T cell co-stimulatory property Closer to in vivo conditions (compared to conventional assays) For T cell co-inhibitory biologics, the 2-cell + format also shows improved assay performance, and reflects T cell co-inhibitory property. 21

21 Acknowledgements Nick Santistevan Lian Tao Tianmeng Shao Weimin Chen Vicky Bushman Jing Zhao Jack Yang Yuan Chang Xu-Rong Jiang Mike Washabaugh Kripa Ram Bioassay group at MedImmune 22

Novel Reporter Gene Bioassays for Immunotherapy Drug Research and Development Jey Cheng, PhD Sr Research Scientist Promega Corporation

Novel Reporter Gene Bioassays for Immunotherapy Drug Research and Development Jey Cheng, PhD Sr Research Scientist Promega Corporation Novel Reporter Gene Bioassays for Immunotherapy Drug Research and Development Jey Cheng, PhD Sr Research Scientist 215 Outline Immune Checkpoint and Combination Therapies Reporter Gene Bioassays: Design,

More information

Reporter Gene Immunotherapy Bioassays

Reporter Gene Immunotherapy Bioassays Reporter Gene Immunotherapy Bioassays Expand the Tool Box for Drug Development in Individual and Combination Immunotherapy Jey Cheng, Ph.D. 215. BEBPA Bioassay Conference September 3, 216 Presentation

More information

ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT

ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS. Choompone Sakonwasun, MD (Hons), FRCPT ACTIVATION AND EFFECTOR FUNCTIONS OF CELL-MEDIATED IMMUNITY AND NK CELLS Choompone Sakonwasun, MD (Hons), FRCPT Types of Adaptive Immunity Types of T Cell-mediated Immune Reactions CTLs = cytotoxic T lymphocytes

More information

Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells

Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells Immunology Basics Relevant to Cancer Immunotherapy: T Cell Activation, Costimulation, and Effector T Cells Andrew H. Lichtman, M.D. Ph.D. Department of Pathology Brigham and Women s Hospital and Harvard

More information

IMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust

IMMUNOTHERAPY FOR CANCER A NEW HORIZON. Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust IMMUNOTHERAPY FOR CANCER A NEW HORIZON Ekaterini Boleti MD, PhD, FRCP Consultant in Medical Oncology Royal Free London NHS Foundation Trust ASCO Names Advance of the Year: Cancer Immunotherapy No recent

More information

Immunotherapy: The Newest Treatment Route

Immunotherapy: The Newest Treatment Route Immunotherapy: The Newest Treatment Route IWMF Patient Forum, Phoenix, AZ Madhav Dhodapkar, MD Professor of Medicine and Immunobiology Chief, Section of Hematology Yale University or the Oldest William

More information

T Cell Activation, Costimulation and Regulation

T Cell Activation, Costimulation and Regulation 1 T Cell Activation, Costimulation and Regulation Abul K. Abbas, MD University of California San Francisco 2 Lecture outline T cell antigen recognition and activation Costimulation, the B7:CD28 family

More information

T Lymphocyte Activation and Costimulation. FOCiS. Lecture outline

T Lymphocyte Activation and Costimulation. FOCiS. Lecture outline 1 T Lymphocyte Activation and Costimulation Abul K. Abbas, MD UCSF FOCiS 2 Lecture outline T cell activation Costimulation, the B7:CD28 family Inhibitory receptors of T cells Targeting costimulators for

More information

Nobel Prize in Physiology or Medicine 2018

Nobel Prize in Physiology or Medicine 2018 Nobel Prize in Physiology or Medicine 2018 Arunika Mukhopadhaya The Nobel Prize in Physiology or Medicine for the year 2018 was awarded to James P Allison of the United States and Tasuku Honjo of Japan

More information

Topics. Humoral Immune Response Part II Accessory cells Fc Receptors Opsonization and killing mechanisms of phagocytes NK, mast, eosynophils

Topics. Humoral Immune Response Part II Accessory cells Fc Receptors Opsonization and killing mechanisms of phagocytes NK, mast, eosynophils Topics Humoral Immune Response Part II Accessory cells Fc Receptors Opsonization and killing mechanisms of phagocytes NK, mast, eosynophils Immune regulation Idiotypic network 2/15/2005 MICR 415 / 515

More information

Tumor Microenvironment and Immune Suppression

Tumor Microenvironment and Immune Suppression Tumor Microenvironment and Immune Suppression Hassane M. Zarour,, MD Department of Medicine, Division of Hematology-Oncology, University of Pittsburgh Cancer Institute Hallmarks of Cancer: The Next Generation

More information

Immune Tolerance. Kyeong Cheon Jung. Department of Pathology Seoul National University College of Medicine

Immune Tolerance. Kyeong Cheon Jung. Department of Pathology Seoul National University College of Medicine Immune Tolerance Kyeong Cheon Jung Department of Pathology Seoul National University College of Medicine Immune tolerance Unresponsiveness to an antigen that is induced by previous exposure to that antigen

More information

Discover the PD-1 pathway and its role in cancer 105/15 -ONCO- 07/15

Discover the PD-1 pathway and its role in cancer 105/15 -ONCO- 07/15 Discover the PD-1 pathway and its role in cancer 105/15 -ONCO- 07/15 Immunology in cancer The role of immunology in cancer Evolving knowledge of the immune system has provided a better understanding of

More information

BIOASSAYS IN PRODUCT DEVELOPMENT: An Immuno-Oncology Perspective

BIOASSAYS IN PRODUCT DEVELOPMENT: An Immuno-Oncology Perspective BIOASSAYS IN PRODUCT DEVELOPMENT: An Immuno-Oncology Perspective CASSS Bioassays May 09, 2017 Tara Stauffer 1 Overview Introduction: Cell-based bioassays in IO product development Immuno-Oncology (IO)

More information

The Adaptive Immune Responses

The Adaptive Immune Responses The Adaptive Immune Responses The two arms of the immune responses are; 1) the cell mediated, and 2) the humoral responses. In this chapter we will discuss the two responses in detail and we will start

More information

Effector T Cells and

Effector T Cells and 1 Effector T Cells and Cytokines Andrew Lichtman, MD PhD Brigham and Women's Hospital Harvard Medical School 2 Lecture outline Cytokines Subsets of CD4+ T cells: definitions, functions, development New

More information

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION

Scott Abrams, Ph.D. Professor of Oncology, x4375 Kuby Immunology SEVENTH EDITION Scott Abrams, Ph.D. Professor of Oncology, x4375 scott.abrams@roswellpark.org Kuby Immunology SEVENTH EDITION CHAPTER 13 Effector Responses: Cell- and Antibody-Mediated Immunity Copyright 2013 by W. H.

More information

VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses. Li Wang. Dartmouth Medical School

VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses. Li Wang. Dartmouth Medical School VISTA, a novel immune checkpoint protein ligand that suppresses anti-tumor tumor T cell responses Li Wang Dartmouth Medical School The B7 Immunoglobulin Super-Family immune regulators APC T cell Co-stimulatory:

More information

Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017

Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Therapeutic Anti-Cancer Vaccines Issue 7 April 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The goal of this MONTHLY

More information

Principles of Adaptive Immunity

Principles of Adaptive Immunity Principles of Adaptive Immunity Chapter 3 Parham Hans de Haard 17 th of May 2010 Agenda Recognition molecules of adaptive immune system Features adaptive immune system Immunoglobulins and T-cell receptors

More information

Antigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS

Antigen Presentation and T Lymphocyte Activation. Abul K. Abbas UCSF. FOCiS 1 Antigen Presentation and T Lymphocyte Activation Abul K. Abbas UCSF FOCiS 2 Lecture outline Dendritic cells and antigen presentation The role of the MHC T cell activation Costimulation, the B7:CD28 family

More information

Natural Killer (NK) cells and Programmed cell death protein-1 (PD-1)

Natural Killer (NK) cells and Programmed cell death protein-1 (PD-1) Natural Killer (NK) cells and Programmed cell death protein-1 (PD-1) Sujan Badal, MS2; Zachary B. Davis, PhD; Jeffrey Miller, MD Department of Medicine, Division of Hematology, Oncology, and Transplantation

More information

IMMUNOBIOLOGY, BIOL 537 Exam # 2 Spring 1997

IMMUNOBIOLOGY, BIOL 537 Exam # 2 Spring 1997 Name I. TRUE-FALSE (1 point each) IMMUNOBIOLOGY, BIOL 537 Exam # 2 Spring 1997 Which of the following is TRUE or FALSE relating to immunogenicity of an antigen and T and B cell responsiveness to antigen?

More information

Chapter 10 (pages ): Differentiation and Functions of CD4+ Effector T Cells Prepared by Kristen Dazy, MD, Scripps Clinic Medical Group

Chapter 10 (pages ): Differentiation and Functions of CD4+ Effector T Cells Prepared by Kristen Dazy, MD, Scripps Clinic Medical Group FIT Board Review Corner September 2015 Welcome to the FIT Board Review Corner, prepared by Andrew Nickels, MD, and Sarah Spriet, DO, senior and junior representatives of ACAAI's Fellows-In-Training (FITs)

More information

NANO 243/CENG 207 Course Use Only

NANO 243/CENG 207 Course Use Only L4: Nanomedicine in Immunotherapy April 12, 2018 Branches of the Immune System Body has two main branches of immunity, innate and adaptive. Innate immunity is the first line of defense. Phagocytes such

More information

Adaptive immune responses: T cell-mediated immunity

Adaptive immune responses: T cell-mediated immunity MICR2209 Adaptive immune responses: T cell-mediated immunity Dr Allison Imrie allison.imrie@uwa.edu.au 1 Synopsis: In this lecture we will discuss the T-cell mediated immune response, how it is activated,

More information

chapter 17: specific/adaptable defenses of the host: the immune response

chapter 17: specific/adaptable defenses of the host: the immune response chapter 17: specific/adaptable defenses of the host: the immune response defense against infection & illness body defenses innate/ non-specific adaptable/ specific epithelium, fever, inflammation, complement,

More information

Immunology. T-Lymphocytes. 16. Oktober 2014, Ruhr-Universität Bochum Karin Peters,

Immunology. T-Lymphocytes. 16. Oktober 2014, Ruhr-Universität Bochum Karin Peters, Immunology T-Lymphocytes 16. Oktober 2014, Ruhr-Universität Bochum Karin Peters, karin.peters@rub.de The role of T-effector cells in the immune response against microbes cellular immunity humoral immunity

More information

Primer on Tumor Immunology. International Society for Biological Therapy of Cancer. C. H. June, M.D. November 10, 2005

Primer on Tumor Immunology. International Society for Biological Therapy of Cancer. C. H. June, M.D. November 10, 2005 Primer on Tumor Immunology International Society for Biological Therapy of Cancer C. H. June, M.D. November 10, 2005 Outline: Primer on Tumor Immunology T Cell Receptors T Cell Biology Tumor immunology

More information

Identification of novel immune regulators of tumor growth using highthroughput

Identification of novel immune regulators of tumor growth using highthroughput Identification of novel immune regulators of tumor growth using highthroughput screening in vivo Tom Brennan 1 Five Prime s Unique Platform Tests Nearly Every Extracellular Protein to Identify Protein

More information

Immune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich

Immune Checkpoints. PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Immune Checkpoints PD Dr med. Alessandra Curioni-Fontecedro Department of Hematology and Oncology Cancer Center Zurich University Hospital Zurich Activation of T cells requires co-stimulation Science 3

More information

T cell-mediated immunity

T cell-mediated immunity T cell-mediated immunity Overview For microbes within phagosomes in phagocytes.cd4+ T lymphocytes (TH1) Activate phagocyte by cytokines studies on Listeria monocytogenes For microbes infecting and replicating

More information

MACROPHAGE "MONOCYTES" SURFACE RECEPTORS

MACROPHAGE MONOCYTES SURFACE RECEPTORS LECTURE: 13 Title: MACROPHAGE "MONOCYTES" SURFACE RECEPTORS LEARNING OBJECTIVES: The student should be able to: Describe the blood monocytes (size, and shape of nucleus). Enumerate some of the monocytes

More information

Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco

Determinants of Immunogenicity and Tolerance. Abul K. Abbas, MD Department of Pathology University of California San Francisco Determinants of Immunogenicity and Tolerance Abul K. Abbas, MD Department of Pathology University of California San Francisco EIP Symposium Feb 2016 Why do some people respond to therapeutic proteins?

More information

Belatacept: An Opportunity to Personalize Immunosuppression? Andrew Adams MD/PhD Emory Transplant Center

Belatacept: An Opportunity to Personalize Immunosuppression? Andrew Adams MD/PhD Emory Transplant Center Belatacept: An Opportunity to Personalize Immunosuppression? Andrew Adams MD/PhD Emory Transplant Center Disclosure Research Funding from BMS. Learning Objectives -Define belatacept-resistant rejection

More information

T cell and Cell-mediated immunity

T cell and Cell-mediated immunity T cell and Cell-mediated immunity ( 第十章 第十二章第十二章 ) Lu Linrong ( 鲁林荣 ) PhD Laboratory of Immune Regulation Institute of Immunology Zhejiang University, School of Medicine Medical Research Building B815-819

More information

Advances in Cancer Immunotherapy

Advances in Cancer Immunotherapy Advances in Cancer Immunotherapy Immunology 101 for the Non-Immunologist Arnold H. Zea, PhD azea@lsuhsc.edu Disclosures No relevant financial relationships to disclose This presentation does not contain

More information

Manuscript: OX40 signaling is involved in the autoactivation of CD4 + CD28 - T cells and contributes to pathogenesis of autoimmune arthritis

Manuscript: OX40 signaling is involved in the autoactivation of CD4 + CD28 - T cells and contributes to pathogenesis of autoimmune arthritis Manuscript: OX40 signaling is involved in the autoactivation of CD4 + CD28 - T cells and contributes to pathogenesis of autoimmune arthritis Vincent Laufer Rheumatology JC October 17 Disclosures NIH 2

More information

Cellular Immune response. Jianzhong Chen, Ph.D Institute of immunology, ZJU

Cellular Immune response. Jianzhong Chen, Ph.D Institute of immunology, ZJU Cellular Immune response Jianzhong Chen, Ph.D Institute of immunology, ZJU Concept of adaptive immune response T cell-mediated adaptive immune response I. Concept of immune response A collective and coordinated

More information

Strategic intervention to enhance/suppress the immune response Examples: Checkpoint blockade Chimeric Antigen Receptors...Bispecific antibodies

Strategic intervention to enhance/suppress the immune response Examples: Checkpoint blockade Chimeric Antigen Receptors...Bispecific antibodies Strategic intervention to enhance/suppress the immune response Examples: Checkpoint blockade Chimeric Antigen Receptors...Bispecific antibodies After decades of investigation establishing principles in

More information

Tim-3 as a target for tumor immunotherapy

Tim-3 as a target for tumor immunotherapy Tim-3 as a target for tumor immunotherapy Ana Carrizosa Anderson Brigham and Women s Hospital Harvard Medical School Disclosures A portion of the work has been performed as part of a sponsored research

More information

Fusion proteins for immune applications (FPIA)

Fusion proteins for immune applications (FPIA) Fusion proteins for immune applications (FPIA) Marie-Paule Lefranc IMGT, the international ImMunoGeneTics information system http://www.imgt.org Fusion proteins for immune applications (FPIA) Fusion proteins

More information

General Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center

General Overview of Immunology. Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center General Overview of Immunology Kimberly S. Schluns, Ph.D. Associate Professor Department of Immunology UT MD Anderson Cancer Center Objectives Describe differences between innate and adaptive immune responses

More information

Acquired Immunity Cells are initially and require before they can work Responds to individual microbes

Acquired Immunity Cells are initially and require before they can work Responds to individual microbes 1 of 10 THE IMMUNE SYSTEM CHAPTER 43; PAGES 898 921 WHY DO WE NEED AN IMMUNE SYSTEM? It s a dirty, dirty world out there and we are vastly outnumbered Bacteria and parasites are everywhere The body has

More information

Bioassays for Quality Control of Cell & Gene Therapy Products

Bioassays for Quality Control of Cell & Gene Therapy Products Bioassays for Quality Control of Cell & Gene Therapy Products Erik Rutjens, Cell & Gene Therapy, Novartis Pharma AG CASSS Bioassays, Silver Spring, March2015 CTL019 Introduction CARTs = Chimeric Antigen

More information

Immunological Tolerance

Immunological Tolerance Immunological Tolerance Introduction Definition: Unresponsiveness to an antigen that is induced by exposure to that antigen Tolerogen = tolerogenic antigen = antigen that induces tolerance Important for

More information

There are 2 major lines of defense: Non-specific (Innate Immunity) and. Specific. (Adaptive Immunity) Photo of macrophage cell

There are 2 major lines of defense: Non-specific (Innate Immunity) and. Specific. (Adaptive Immunity) Photo of macrophage cell There are 2 major lines of defense: Non-specific (Innate Immunity) and Specific (Adaptive Immunity) Photo of macrophage cell Development of the Immune System ery pl neu mφ nk CD8 + CTL CD4 + thy TH1 mye

More information

Immunology. Overview. Kris.ne Kra1s, M.D.

Immunology. Overview. Kris.ne Kra1s, M.D. Immunology Overview Kris.ne Kra1s, M.D. Immunology Overview Defini.ons Cells Lymphocytes An.gen-presen.ng cells Effector cells Responses The innate immune response Capturing and displaying an.gens Cell-mediated

More information

Antigen Recognition by T cells

Antigen Recognition by T cells Antigen Recognition by T cells TCR only recognize foreign Ags displayed on cell surface These Ags can derive from pathogens, which replicate within cells or from pathogens or their products that cells

More information

Immunology for the Rheumatologist

Immunology for the Rheumatologist Immunology for the Rheumatologist Rheumatologists frequently deal with the immune system gone awry, rarely studying normal immunology. This program is an overview and discussion of the function of the

More information

Immunology of Asthma. Kenneth J. Goodrum,Ph. Ph.D. Ohio University College of Osteopathic Medicine

Immunology of Asthma. Kenneth J. Goodrum,Ph. Ph.D. Ohio University College of Osteopathic Medicine Immunology of Asthma Kenneth J. Goodrum,Ph Ph.D. Ohio University College of Osteopathic Medicine Outline! Consensus characteristics! Allergens:role in asthma! Immune/inflammatory basis! Genetic basis!

More information

Innate immunity (rapid response) Dendritic cell. Macrophage. Natural killer cell. Complement protein. Neutrophil

Innate immunity (rapid response) Dendritic cell. Macrophage. Natural killer cell. Complement protein. Neutrophil 1 The immune system The immune response The immune system comprises two arms functioning cooperatively to provide a comprehensive protective response: the innate and the adaptive immune system. The innate

More information

Prepared by Cyrus H. Nozad, MD, University of Tennessee and John Seyerle, MD, Ohio State University

Prepared by Cyrus H. Nozad, MD, University of Tennessee and John Seyerle, MD, Ohio State University Allergy and Immunology Review Corner: Chapter 21 of Middleton s Allergy Principles and Practice, Seventh Edition, edited by N. Franklin Adkinson, et al. Chapter 21: Antigen-Presenting Dendritic Cells (Pages

More information

Adaptive Immunity: Humoral Immune Responses

Adaptive Immunity: Humoral Immune Responses MICR2209 Adaptive Immunity: Humoral Immune Responses Dr Allison Imrie 1 Synopsis: In this lecture we will review the different mechanisms which constitute the humoral immune response, and examine the antibody

More information

Radiation Therapy as an Immunomodulator

Radiation Therapy as an Immunomodulator Radiation Therapy as an Immunomodulator Yvonne Mowery, MD, PhD February 20, 2017 Tumor/Immune System Balance Kalbasi, JCI 2013 UNC-Duke-NC State-Wake Forest Spring 2017 2 RT Can Shift Balance Toward Elimination

More information

Cell Mediated Immunity (I) Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel:

Cell Mediated Immunity (I) Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel: Cell Mediated Immunity (I) Dr. Aws Alshamsan Department of Pharmaceu5cs Office: AA87 Tel: 4677363 aalshamsan@ksu.edu.sa Learning Objectives By the end of this lecture you will be able to: 1 Understand

More information

Cancer immunity and immunotherapy. General principles

Cancer immunity and immunotherapy. General principles 1 Cancer immunity and immunotherapy Abul K. Abbas UCSF General principles 2 The immune system recognizes and reacts against cancers The immune response against tumors is often dominated by regulation or

More information

VMC-221: Veterinary Immunology and Serology (1+1) Question Bank

VMC-221: Veterinary Immunology and Serology (1+1) Question Bank VMC-221: Veterinary Immunology and Serology (1+1) Objective type Questions Question Bank Q. No. 1 - Fill up the blanks with correct words 1. The British physician, who developed the first vaccine against

More information

Chapter 23 Immunity Exam Study Questions

Chapter 23 Immunity Exam Study Questions Chapter 23 Immunity Exam Study Questions 1. Define 1) Immunity 2) Neutrophils 3) Macrophage 4) Epitopes 5) Interferon 6) Complement system 7) Histamine 8) Mast cells 9) Antigen 10) Antigens receptors 11)

More information

Bioactivity Assays: Putting the Puzzle Together

Bioactivity Assays: Putting the Puzzle Together Bioactivity Assays: Putting the Puzzle Together Dr. Ulrike Herbrand Department for Biosafety & Bioassay Services Charles River Biologics Testing Solutions Outline General Remarks MoA reflecting bioassays

More information

TEMA 5. ANTICUERPOS Y SUS RECEPTORES

TEMA 5. ANTICUERPOS Y SUS RECEPTORES TEMA 5. ANTICUERPOS Y SUS RECEPTORES The B-cell antigen receptor (left) consists of two identical heavy (H) chains and two identical light (L) chains. In addition, secondary components (Ig-α and Ig-β)

More information

Central tolerance. Mechanisms of Immune Tolerance. Regulation of the T cell response

Central tolerance. Mechanisms of Immune Tolerance. Regulation of the T cell response Immunoregulation: A balance between activation and suppression that achieves an efficient immune response without damaging the host. Mechanisms of Immune Tolerance ACTIVATION (immunity) SUPPRESSION (tolerance)

More information

Mechanisms of Immune Tolerance

Mechanisms of Immune Tolerance Immunoregulation: A balance between activation and suppression that achieves an efficient immune response without damaging the host. ACTIVATION (immunity) SUPPRESSION (tolerance) Autoimmunity Immunodeficiency

More information

Adaptive Immunity: Specific Defenses of the Host

Adaptive Immunity: Specific Defenses of the Host 17 Adaptive Immunity: Specific Defenses of the Host SLOs Differentiate between innate and adaptive immunity, and humoral and cellular immunity. Define antigen, epitope, and hapten. Explain the function

More information

Immunology and Immunotherapy 101 for the Non-Immunologist

Immunology and Immunotherapy 101 for the Non-Immunologist Immunology and Immunotherapy 101 for the Non-Immunologist Stephen P. Schoenberger, Ph.D La Jolla Institute for Allergy and Immunology & UCSD Moores Cancer Center Disclosures Human Longevity Inc: Salary

More information

Autoimmunity. Autoimmunity arises because of defects in central or peripheral tolerance of lymphocytes to selfantigens

Autoimmunity. Autoimmunity arises because of defects in central or peripheral tolerance of lymphocytes to selfantigens Autoimmunity Autoimmunity arises because of defects in central or peripheral tolerance of lymphocytes to selfantigens Autoimmune disease can be caused to primary defects in B cells, T cells and possibly

More information

Chapter 1. Chapter 1 Concepts. MCMP422 Immunology and Biologics Immunology is important personally and professionally!

Chapter 1. Chapter 1 Concepts. MCMP422 Immunology and Biologics Immunology is important personally and professionally! MCMP422 Immunology and Biologics Immunology is important personally and professionally! Learn the language - use the glossary and index RNR - Reading, Note taking, Reviewing All materials in Chapters 1-3

More information

Adaptive Immune System

Adaptive Immune System Short Course on Immunology Adaptive Immune System Bhargavi Duvvuri Ph.D IIIrd Year (Immunology) bhargavi@yorku.ca Supervisor Dr.Gillian E Wu Professor, School of Kinesiology and Health Sciences York University,

More information

Understanding the Regulation of Antigen Specific T Helper Cells by Cytokines and Costimulatory Molecules Expressed on distintct Antigen Prtesenting

Understanding the Regulation of Antigen Specific T Helper Cells by Cytokines and Costimulatory Molecules Expressed on distintct Antigen Prtesenting Researcher : Vinod Singh (2003) SUMMARY ---.,.-:-.., Guide : Agrewala, J.N.(Dr.) Understanding the Regulation of Antigen Specific T Helper Cells by Cytokines and Costimulatory Molecules Expressed on distintct

More information

NKTR-214 plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology

NKTR-214 plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology plus NKTR-262, a Scientifically-Guided Rational Combination Approach for Immune Oncology Jonathan Zalevsky SVP, Biology and Preclinical Development Nektar Therapeutics World Preclinical Congress, 2017

More information

Lecture outline. Immunological tolerance and immune regulation. Central and peripheral tolerance. Inhibitory receptors of T cells. Regulatory T cells

Lecture outline. Immunological tolerance and immune regulation. Central and peripheral tolerance. Inhibitory receptors of T cells. Regulatory T cells 1 Immunological tolerance and immune regulation Abul K. Abbas UCSF 2 Lecture outline Central and peripheral tolerance Inhibitory receptors of T cells Regulatory T cells 1 The immunological equilibrium:

More information

Data Sheet TIGIT / NFAT Reporter - Jurkat Cell Line Catalog #60538

Data Sheet TIGIT / NFAT Reporter - Jurkat Cell Line Catalog #60538 Data Sheet TIGIT / NFAT Reporter - Jurkat Cell Line Catalog #60538 Background: TIGIT is a co-inhibitory receptor that is highly expressed in Natural Killer (NK) cells, activated CD4+, CD8+ and regulatory

More information

NEUTROPHIL, BASOPHIL, EOSINOPHIL, AND PLATELETS SURFACE RECEPTORS

NEUTROPHIL, BASOPHIL, EOSINOPHIL, AND PLATELETS SURFACE RECEPTORS LECTURE: 15 Title NEUTROPHIL, BASOPHIL, EOSINOPHIL, AND PLATELETS SURFACE RECEPTORS LEARNING OBJECTIVES: The student should be able to: Determine the relative percentages in blood for the various types

More information

ACTIVATION OF T LYMPHOCYTES AND CELL MEDIATED IMMUNITY

ACTIVATION OF T LYMPHOCYTES AND CELL MEDIATED IMMUNITY ACTIVATION OF T LYMPHOCYTES AND CELL MEDIATED IMMUNITY The recognition of specific antigen by naïve T cell induces its own activation and effector phases. T helper cells recognize peptide antigens through

More information

Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017

Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Delivering a Competitive Intelligence Advantage Immuno-Oncology Clinical Trials Update: Checkpoint Inhibitors Others (not Anti-PD-L1/PD-1) Issue 4 January 2017 Immuno-Oncology CLINICAL TRIALS UPDATE The

More information

Attribution: University of Michigan Medical School, Department of Microbiology and Immunology

Attribution: University of Michigan Medical School, Department of Microbiology and Immunology Attribution: University of Michigan Medical School, Department of Microbiology and Immunology License: Unless otherwise noted, this material is made available under the terms of the Creative Commons Attribution

More information

Venky Ramakrishna PhD Celldex Therapeutics, Hampton NJ, USA

Venky Ramakrishna PhD Celldex Therapeutics, Hampton NJ, USA Antibody Targeting of Human CD27 with Varlilumab (CDX-1127) identifies genes and pathways related to inflammation Venky Ramakrishna PhD Celldex Therapeutics, Hampton NJ, USA www.celldextherapeutics.com

More information

Therapy Of Cancer: Which Cells Are Important, And How To Assay Their Activity

Therapy Of Cancer: Which Cells Are Important, And How To Assay Their Activity ADCC Effector Cells In Antibody Therapy Of Cancer: Which Cells Are Important, And How To Assay Their Activity M. Jules Mattes Potential ADCC effector cells and their Fcγ receptors Cell type Fcγ receptors

More information

Disclosure Information. Mary L. Disis

Disclosure Information. Mary L. Disis Disclosure Information Mary L. Disis I have the following financial relationships to disclose: Consultant for: VentiRx, Celgene, Emergent, EMD Serono Speaker s Bureau for: N/A Grant/Research support from:

More information

Immune system. Self/non-self recognition. Memory. The state of protection from infectious disease. Acceptance vs rejection

Immune system. Self/non-self recognition. Memory. The state of protection from infectious disease. Acceptance vs rejection Immune system The state of protection from infectious disease Self/non-self recognition 自我 非我 Acceptance vs rejection Memory 疫苗 2 Microbes Commensal Microbes 共生菌 Normal flora: usually confined to certain

More information

Lecture 4. T lymphocytes

Lecture 4. T lymphocytes Lecture 4 T lymphocytes Objectives Mention the types of T cells List the Types of T helper cell (CD4+) Discuss the Activation of T cells Define Interleukins Distinguish the Super Ag from ordinary Ag Show

More information

Immunology Lecture 4. Clinical Relevance of the Immune System

Immunology Lecture 4. Clinical Relevance of the Immune System Immunology Lecture 4 The Well Patient: How innate and adaptive immune responses maintain health - 13, pg 169-181, 191-195. Immune Deficiency - 15 Autoimmunity - 16 Transplantation - 17, pg 260-270 Tumor

More information

Lecture 9: T-cell Mediated Immunity

Lecture 9: T-cell Mediated Immunity Lecture 9: T-cell Mediated Immunity Questions to Consider How do T cells know where to go? Questions to Consider How do T cells know where to go? How does antigen get targeted to a T cell expressing the

More information

CELL BIOLOGY - CLUTCH CH THE IMMUNE SYSTEM.

CELL BIOLOGY - CLUTCH CH THE IMMUNE SYSTEM. !! www.clutchprep.com CONCEPT: OVERVIEW OF HOST DEFENSES The human body contains three lines of against infectious agents (pathogens) 1. Mechanical and chemical boundaries (part of the innate immune system)

More information

TCR, MHC and coreceptors

TCR, MHC and coreceptors Cooperation In Immune Responses Antigen processing how peptides get into MHC Antigen processing involves the intracellular proteolytic generation of MHC binding proteins Protein antigens may be processed

More information

Introduction to Immune System

Introduction to Immune System Introduction to Immune System Learning outcome You will be able to understand, at a fundamental level, the STRUCTURES and FUNCTIONS of cell surface and soluble molecules involved in recognition of foreign

More information

T Cell Activation Bioassay (IL-2) Instructions for use of Products J1651 and J1655.

T Cell Activation Bioassay (IL-2) Instructions for use of Products J1651 and J1655. TECHNICAL MANUAL T Cell Activation Bioassay (IL-2) Instructions for use of Products J1651 and J1655. 11/16 TM492 T Cell Activation Bioassay (IL-2) All technical literature is available at: www.promega.com/protocols/

More information

Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D.

Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies. Michael A. Curran, Ph.D. Understanding Checkpoint Inhibitors: Approved Agents, Drugs in Development and Combination Strategies Michael A. Curran, Ph.D. MD Anderson Cancer Center Department of Immunology Disclosures I have research

More information

Immunology MIMM-314 MID-TERM II EXAMINATION. 1 hour between 8:30 a.m. - 10:00 a.m. McIntyre Medical Rm 504 (Martin Amphitheatre)

Immunology MIMM-314 MID-TERM II EXAMINATION. 1 hour between 8:30 a.m. - 10:00 a.m. McIntyre Medical Rm 504 (Martin Amphitheatre) GROUP (Version) 1 Annotated version April 8, 2011, RGEP DEPARTMENT OF MICROBIOLOGY AND IMMUNOLOGY Immunology MIMM-314 MID-TERM II EXAMINATION Course Coordinator: Dr. Roger Palfree Date: Thursday, March

More information

Major Histocompatibility Complex (MHC) and T Cell Receptors

Major Histocompatibility Complex (MHC) and T Cell Receptors Major Histocompatibility Complex (MHC) and T Cell Receptors Historical Background Genes in the MHC were first identified as being important genes in rejection of transplanted tissues Genes within the MHC

More information

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer

TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer AD Award Number: W8XWH-5-- TITLE: Development of Antigen Presenting Cells for adoptive immunotherapy in prostate cancer PRINCIPAL INVESTIGATOR: Mathias Oelke Ph.D. CONTRACTING ORGANIZATION: Johns Hopkins

More information

The PD-1 pathway of T cell exhaustion

The PD-1 pathway of T cell exhaustion The PD-1 pathway of T cell exhaustion SAMO 18.3.2016 Overview T cell exhaustion Biology of PD-1 Mechanism Ligands expressed on tumor cell and on non-tumor cells other receptor pairs Biomarkers for apd-1/pd-l1

More information

PD-L1 Expression and Signaling by Tumors and Macrophages: Comparative Studies in Mice and Dogs

PD-L1 Expression and Signaling by Tumors and Macrophages: Comparative Studies in Mice and Dogs PD-L1 Expression and Signaling by Tumors and Macrophages: Comparative Studies in Mice and Dogs Steven Dow, DVM, PhD Department of Clinical Sciences, Animal Cancer Center Colorado State University Consortium

More information

FOCiS. Lecture outline. The immunological equilibrium: balancing lymphocyte activation and control. Immunological tolerance and immune regulation -- 1

FOCiS. Lecture outline. The immunological equilibrium: balancing lymphocyte activation and control. Immunological tolerance and immune regulation -- 1 1 Immunological tolerance and immune regulation -- 1 Abul K. Abbas UCSF FOCiS 2 Lecture outline Principles of immune regulation Self-tolerance; mechanisms of central and peripheral tolerance Inhibitory

More information

محاضرة مناعت مدرس المادة :ا.م. هدى عبدالهادي علي النصراوي Immunity to Infectious Diseases

محاضرة مناعت مدرس المادة :ا.م. هدى عبدالهادي علي النصراوي Immunity to Infectious Diseases محاضرة مناعت مدرس المادة :ا.م. هدى عبدالهادي علي النصراوي Immunity to Infectious Diseases Immunity to infection depends on a combination of innate mechanisms (phagocytosis, complement, etc.) and antigen

More information

C. Incorrect! MHC class I molecules are not involved in the process of bridging in ADCC.

C. Incorrect! MHC class I molecules are not involved in the process of bridging in ADCC. Immunology - Problem Drill 13: T- Cell Mediated Immunity Question No. 1 of 10 1. During Antibody-dependent cell mediated cytotoxicity (ADCC), the antibody acts like a bridge between the specific antigen

More information

Adaptive (acquired) immunity. Professor Peter Delves University College London

Adaptive (acquired) immunity. Professor Peter Delves University College London Adaptive (acquired) immunity Professor Peter Delves University College London p.delves@ucl.ac.uk Haematopoiesis Haematopoiesis Lymphocytes = adaptive response Recognition of pathogens by adaptive cells,

More information

Adaptive Immunity. Jeffrey K. Actor, Ph.D. MSB 2.214,

Adaptive Immunity. Jeffrey K. Actor, Ph.D. MSB 2.214, Adaptive Immunity Jeffrey K. Actor, Ph.D. MSB 2.214, 500-5344 Lecture Objectives: Understand role of various molecules including cytokines, chemokines, costimulatory and adhesion molecules in the development

More information

Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD.

Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Allergy and Immunology Review Corner: Chapter 19 of Immunology IV: Clinical Applications in Health and Disease, by Joseph A. Bellanti, MD. Chapter 19: Tolerance, Autoimmunity, and Autoinflammation Prepared

More information

1. Overview of Adaptive Immunity

1. Overview of Adaptive Immunity Chapter 17A: Adaptive Immunity Part I 1. Overview of Adaptive Immunity 2. T and B Cell Production 3. Antigens & Antigen Presentation 4. Helper T cells 1. Overview of Adaptive Immunity The Nature of Adaptive

More information